Publication:
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Simple item page
dc.contributor.authorAli T. Taheren_US
dc.contributor.authorZeynep Karakasen_US
dc.contributor.authorElena Cassinerioen_US
dc.contributor.authorNoppadol Siritanaratkulen_US
dc.contributor.authorAntonis Kattamisen_US
dc.contributor.authorAurelio Maggioen_US
dc.contributor.authorStefano Rivellaen_US
dc.contributor.authorNorbert Hollaenderen_US
dc.contributor.authorBruyere Mahuzieren_US
dc.contributor.authorBrian Gadbawen_US
dc.contributor.authorYesim Aydinoken_US
dc.contributor.otherAmerican University of Beirut Medical Centeren_US
dc.contributor.otherUniversità degli Studi di Milanoen_US
dc.contributor.otherThe Children's Hospital of Philadelphiaen_US
dc.contributor.otherNational and Kapodistrian University of Athensen_US
dc.contributor.otherNovartis Pharma S.A.S.en_US
dc.contributor.otherIstanbul Üniversitesi Tıp Fakültesien_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherNovartis International AGen_US
dc.contributor.otherEge University Medical Schoolen_US
dc.contributor.otherNovartis Pharmaceuticals Corporationen_US
dc.contributor.otherUOSD MICI-A.O. Ospedali Riuniti “Villa Sofia-Cervello” Palermoen_US
dc.date.accessioned2019-08-23T10:38:19Z
dc.date.available2019-08-23T10:38:19Z
dc.date.issued2018-01-11en_US
dc.identifier.citationBlood. Vol.131, No.2 (2018), 263-265en_US
dc.identifier.doi10.1182/blood-2017-06-790121en_US
dc.identifier.issn15280020en_US
dc.identifier.issn00064971en_US
dc.identifier.other2-s2.0-85040441699en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/45268
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040441699&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleEfficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a studyen_US
dc.typeLetteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040441699&origin=inwarden_US

Files

Collections

Scopus 2018

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.